



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/524,643
				Filing Date	February 10, 2005
				First Named Inventor	Hideki GARREN
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	022259-001010US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
/NMM/	1	US-6,194,388 B1	02-27-2001	Krieg et al.	
↓	2	US-6,225,292 B1	05-01-2001	Raz et al.	
	3	US-2002/0164341 A1	11-07-2002	Davis et al.	
	4	US-2003/0181406 A1	09-25-2003	Schetter et al.	
/NMM/					

NON PATENT LITERATURE DOCUMENTS					T ²
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/NMM/	5	HO et al., "An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems", <u>J. Immunology</u> , 2003, pp. 4920-4926, Vol. 171.			<input checked="" type="checkbox"/>
↓	6	KLINMAN et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ", <u>Proc Nat. Acad. U.S.A.</u> , 1996, pp. 2879-2883, Vol. 93.			<input checked="" type="checkbox"/>
	7	KRIEG et al., "CpG motifs in bacterial DNA trigger direct B-Cell activation", <u>Nature</u> , 1995, pp. 546-549, Vol. 374.			<input checked="" type="checkbox"/>
	8	MARTIN-OROZCO et al., "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences", <u>Int. Immunol.</u> , 1999, pp. 1111-1118, Vol. 11(7).			<input checked="" type="checkbox"/>
	9	SPARWASSER et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <u>Eur. J. Immunol.</u> , 1998, pp. 2045-2054, Vol. 28.			<input checked="" type="checkbox"/>
	10	STACEY et al., "Immunostimulatory DNA as an adjuvant in vaccination against <i>Leishmania major</i> ", <u>Infection and Immunity</u> , 1999, pp. 3719-3726, Vol. 67(8).			<input checked="" type="checkbox"/>
	11	YI et al., "Rapid Immune Activation by CpG Motifs in Bacterial DNA", <u>J. Immunol.</u> , 1996, pp. 5394-5402, Vol. 157.			<input checked="" type="checkbox"/>
/NMM/	12	ZEUNER et al., "Reduction of CpG-Induced Arthritis by Suppressive Oligodeoxynucleotides", <u>Arthritis and Rheumatism</u> , 2002, pp. 2219-2224, Vol. 46(8).			<input checked="" type="checkbox"/>

Examiner Signature	/N. M. Minnifield/ (09/26/2007)	Date Considered	09/26/2007
-----------------------	---------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if reference is attached.



Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/524,643
				Filing Date	February 10, 2005
				First Named Inventor	Garren, Hideki
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	022259-001010US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/NMM/	AA	WO	01/51626	A2	07-19-2001			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/NMM/	AB	LENERT, Petar et al.; "CpG Stimulation of Primary Mouse B Cells is Blocked by Inhibitory Oligodeoxyribonucleotides at a Site Proximal to NF-κB Activation"; 2001, <u>Antisense & Nucleic Acid Drug Development</u> , Vol. 11, pp. 247-256.	<input type="checkbox"/>
/NMM/	AC	YEW, Nelson S. et al.; "Reduced Inflammatory Response to Plasmid DNA Vectors by Elimination and Inhibition of Immunostimulatory CpG Motifs"; 2000, <u>Molecular Therapy</u> , Vol. 1, No. 3, pp. 255-262.	<input type="checkbox"/>
/NMM/	AD	INVITROGEN: "pVAX1 (Catalog no. V260-20) version B 010124/25-0256, 1998, 15 pages.	<input type="checkbox"/>

Examiner Signature	/N. M. Minnifield/ (09/26/2007)	Date Considered	09/26/2007
-----------------------	---------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.